What is Cagrilintide?
Cagrilintide is an investigational peptide that has gained attention for its potential role in appetite control and weight management. It is a long-acting analog of amylin, a hormone naturally released by the pancreas alongside insulin. While amylin has been known for decades to help regulate satiety and food intake, its short natural half-life limited its therapeutic usefulness. Cagrilintide was designed to overcome this limitation, offering prolonged activity and renewed interest in amylin-based treatments for obesity and metabolic disease.
What Is Amylin?
Amylin is a hormone secreted from the pancreas during meals. In fact, amylin and insulin are packaged together (in synaptic vesicles) and released with meals simultaneously. Amylin works in parallel with insulin to help regulate blood sugar and appetite. Amylin slows gastric emptying, suppresses excess glucagon release, and signals the brain to promote feelings of fullness. In people with obesity or type 2 diabetes, amylin signaling may be impaired, contributing to overeating and difficulty maintaining weight loss.
How Does Cagrilintide Work?
Cagrilintide binds to amylin receptors in the brain, particularly in areas involved in appetite regulation and satiety. By activating these pathways, it helps reduce hunger, increase feelings of fullness, and decrease overall caloric intake. Its long-acting design allows for sustained receptor activation, which may lead to more consistent appetite suppression compared to native amylin.
What is Cagrilintide Used for?
Cagrilintide is currently being studied primarily for:
- Chronic weight management
- Obesity-related metabolic conditions
- Adjunct therapy with GLP-1 agonists (retatrutide, tirzepatide, and semaglutide) to potentiate their effects
That said, human data is limited. Because cagrilintide is not FDA-approved, its long-term safety, ideal dosing, and full risk profile in humans are not yet fully understood.
Side Effects of Cagrilintide
The most commonly reported side effects of amylin-based therapies are gastrointestinal, including nausea and reduced appetite. These effects are generally dose-related and may lessen over time. Because cagrilintide is still investigational, long-term safety data is limited, and it is not yet approved for general clinical use.
Early studies suggest that amylin analogs like cagrilintide may help address weight-loss plateaus and improve long-term adherence by enhancing satiety without relying solely on appetite suppression.
Cagrilintide Dosing Protocol (for Research)
Cagrilintide is effective, per research/educational protocols, when administered under the skin by injection (subcutaneous).
Independent researchers recommend combining cagrilintide with a GLP-1 agonist, such as semaglutide, tirzepatide, or retatrutide. When used in combination, it produces synergistic effects for weight loss and diabetes control.
Recommended research dosing protocol:
| Phase | Dose & frequency |
|---|---|
| Weeks 1–2 | 0.6 mg/week |
| Weeks 3–4 | 1.2 mg/week |
| Weeks 5–6 | 2.4 mg/week |
| Weeks 7 and beyond | 4.8 mg/week |
Shown for education. A licensed clinician should set any actual dose. Compare protocols across peptides in the peptide dosage chart.
How to prepare the vialConvert a dose to units →
Using a retatrutide/cagrilintide blend vial? Open the blend calculator →
Common questions about Cagrilintide
What is Cagrilintide?
Cagrilintide is an investigational peptide that has gained attention for its potential role in appetite control and weight management. It is a long-acting analog of amylin, a hormone naturally released by the pancreas alongside insulin.
What is Cagrilintide used for?
Cagrilintide is currently being studied primarily for: Chronic weight management; Obesity-related metabolic conditions; Adjunct therapy with GLP-1 agonists (retatrutide, tirzepatide, and semaglutide) to potentiate their effects.
How does Cagrilintide work?
Cagrilintide binds to amylin receptors in the brain, particularly in areas involved in appetite regulation and satiety. By activating these pathways, it helps reduce hunger, increase feelings of fullness, and decrease overall caloric intake.
What are the side effects of Cagrilintide?
The most commonly reported side effects of amylin-based therapies are gastrointestinal, including nausea and reduced appetite. These effects are generally dose-related and may lessen over time.
What is the dosage of Cagrilintide?
One commonly referenced research protocol is: Weeks 1–2: 0.6 mg/week; Weeks 3–4: 1.2 mg/week; Weeks 5–6: 2.4 mg/week; Weeks 7 and beyond: 4.8 mg/week. Shown for education only; a licensed clinician should set any actual dose. See the dosing table.
How do you mix (reconstitute) Cagrilintide?
Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.
How much bacteriostatic water do you add to Cagrilintide?
There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.
Is Cagrilintide FDA-approved?
No. Cagrilintide is investigational and is not FDA-approved in the US (status as of October 2026).
References
- Hay DL, at al. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67:564-600. doi: 10.1124/pr.115.010629. View source
- Mathiesen DS, et al. Long-acting amylin analogues for the management of obesity. Curr Opin Endocrinol Diabetes Obes. 2022;29:183-190. doi: 10.1097/MED.0000000000000716. View source
- Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025 Aug 14;393(7):648-659. doi: 10.1056/NEJMoa2502082. Epub 2025 Jun 22. PMID: 40544432. View source